Search clinical trials for: OPT-822/OPT-821(30 μg/100 μg)

Total 16 results

Mackay Memorial Hospital
OBI Pharma, Inc

Unknown

Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer

Ovarian Cancer

Taiwan
OBI Pharma, Inc

Completed

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

Metastatic Breast Cancer

United States, Taiwan, Korea, Republic of, China, India
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
MabVax Therapeutics, Inc.

Completed

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Sarcoma

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Neuroblastoma | High-risk Neuroblastoma | Metastatic Neuroblastoma

United States
Baylor College of Medicine
George Washington University; Children's National Research Institute

Completed

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant

Hookworm Infection | Hookworm Disease

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Neuroblastoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditions

United States
Ferring Pharmaceuticals

Completed

Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Nocturia

Japan
Baylor College of Medicine

Completed

Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults

Hookworm Infection | Hookworm Disease

Brazil
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics

Active, not recruiting

Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Neuroblastoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acid

Lung Cancer

United States
University Hospital, Basel, Switzerland
Swiss National Science Foundation; ModernaTX, Inc.

Completed

Immunocompromised Swiss Cohorts Based Trial Platform (COVERALL)

Immunocompromised Patients

Switzerland
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Completed

Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Ovarian Cancer | Peritoneal Cancer | Fallopian Tubes Cancer

United States
Prof. Dr. med. Claus Rödel

Active, not recruiting

Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Rectal Cancer Stage III

Germany

Search clinical trials for: OPT-822/OPT-821(30 μg/100 μg)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations